These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 33171668)
1. Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis. Skurikhin E; Nebolsin V; Widera D; Ermakova N; Pershina O; Pakhomova A; Krupin V; Pan E; Zhukova M; Novikov F; Sandrikina L; Morozov S; Kubatiev A; Dygai A Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171668 [TBL] [Abstract][Full Text] [Related]
2. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients. Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908 [TBL] [Abstract][Full Text] [Related]
3. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib. Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis. Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203 [TBL] [Abstract][Full Text] [Related]
6. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Moodley Y; Corte T; Richeldi L; King TE Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967 [TBL] [Abstract][Full Text] [Related]
7. Pirfenidone and nintedanib exert additive antifibrotic effects by the SPP1-AKT pathway in macrophages and fibroblasts. Meng C; Fan G; Liu J; Tao N; Sun T Biochem Biophys Res Commun; 2024 Jul; 716():150020. PubMed ID: 38692011 [TBL] [Abstract][Full Text] [Related]
8. Precision-cut lung slices from bleomycin treated animals as a model for testing potential therapies for idiopathic pulmonary fibrosis. Cedilak M; Banjanac M; Belamarić D; Paravić Radičević A; Faraho I; Ilić K; Čužić S; Glojnarić I; Eraković Haber V; Bosnar M Pulm Pharmacol Ther; 2019 Apr; 55():75-83. PubMed ID: 30776489 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects. Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610 [TBL] [Abstract][Full Text] [Related]
10. Micro-CT-assisted identification of the optimal time-window for antifibrotic treatment in a bleomycin mouse model of long-lasting pulmonary fibrosis. Buccardi M; Grandi A; Ferrini E; Buseghin D; Villetti G; Civelli M; Sverzellati N; Aliverti A; Pennati F; Stellari FF Sci Rep; 2024 Jun; 14(1):14792. PubMed ID: 38926490 [TBL] [Abstract][Full Text] [Related]
11. [Antifibrotic therapy and progressive lung fibrosis]. Fellrath JM Rev Med Suisse; 2020 Jun; 16(698):1256-1260. PubMed ID: 32558455 [TBL] [Abstract][Full Text] [Related]
12. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Kim TH; Lee YH; Kim KH; Lee SH; Cha JY; Shin EK; Jung S; Jang AS; Park SW; Uh ST; Kim YH; Park JS; Sin HG; Youm W; Koh ES; Cho SY; Paik YK; Rhim TY; Park CS Am J Respir Crit Care Med; 2010 Sep; 182(5):633-42. PubMed ID: 20463180 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of pirfenidone in a sheep model of pulmonary fibrosis. Dewage SNV; Organ L; Koumoundouros E; Derseh HB; Perera KUE; Samuel CS; Stent AW; Snibson KJ Exp Lung Res; 2019; 45(9-10):310-322. PubMed ID: 31762329 [TBL] [Abstract][Full Text] [Related]
14. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681 [TBL] [Abstract][Full Text] [Related]
15. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302 [TBL] [Abstract][Full Text] [Related]
16. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly. Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580 [TBL] [Abstract][Full Text] [Related]